跳转至内容
Merck
所有图片(1)

文件

N2260

Supelco

D(-)-炔诺孕酮

analytical standard

别名:

18,19-双失碳-13β-乙基-17β-羟基-孕甾-4-烯-20-炔基-3-酮, 18,19-双失碳孕甾-4-烯-20-炔基-3-酮, 左旋甲基炔诺酮, 左炔诺孕酮, 甲基炔诺酮

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C21H28O2
CAS号:
797-63-7
分子量:
312.45
EC號碼:
212-349-8
MDL號碼:
MFCD00199013
分類程式碼代碼:
41116107
PubChem物質ID:
329818600
NACRES:
NA.24

等級

analytical standard

品質等級

200

化驗

≥99%

技術

HPLC: suitable
gas chromatography (GC): suitable

應用

forensics and toxicology
veterinary

格式

neat

儲存溫度

2-8°C

SMILES 字串

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

InChI 密鑰

WWYNJERNGUHSAO-XUDSTZEESA-N

基因資訊

human ... PGR(5241)
rat ... Ar(24208)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般說明

D(−)-Norgestrel is a hormonal medication and a contraceptive used by women.

應用

D(−)-Norgestrel may be used as a reference standard for the analysis of the analyte in human plasma using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS).
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

象形圖

Health hazard
GHS08

訊號詞

Danger

危險聲明

H351,H360D,H362

危險分類

Carc. 2 - Lact. - Repr. 1A

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number
0000324610
0000333426
0000333425
SLCR5189
0000248250

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Analytical Methods for Therapeutic Drug Monitoring and Toxicology (2011)
Alice W Y Wong et al.
Obstetrics and gynecology, 121(5), 943-950 (2013-05-03)
To estimate the rate of endometrial pathology with the prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen. This was a randomized contro-lled trial of 129 Chinese women who attended a university hospital in Hong
Abbey B Berenson et al.
Obstetrics and gynecology, 121(5), 951-958 (2013-05-03)
Many U.S. health care providers remain reluctant to prescribe intrauterine devices (IUDs) to teenagers as a result of concerns about serious complications. This study examined whether 15-19-year-old IUD users were more likely to experience complications, failure, or early discontinuation than
Anita Nelson et al.
Obstetrics and gynecology, 122(6), 1205-1213 (2013-11-19)
To evaluate the efficacy and safety of two low-dose levonorgestrel intrauterine contraceptive systems. Nulliparous and parous women aged 18-35 years with regular menstrual cycles (21-35 days) requesting contraception were randomized to 3 years of treatment with one of two levonorgestrel
Satu Heliövaara-Peippo et al.
American journal of obstetrics and gynecology, 209(6), 535-535 (2013-09-04)
Menorrhagia is a common problem impairing the quality of life (QOL) of many women. Both levonorgestrel-releasing intrauterine system (LNG-IUS) and hysterectomy are effective treatment modalities but no long-term comparative studies of QOL and costs exist. The objective of this study
查看所有相关文献

Chromatograms

application for HPLC

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门